With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary ...

The year saw much-anticipated data on the value of early TAVI vs surveillance, plus two new tricuspid device approvals.